secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001157523-22-001587
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra Q3 net loss $14.6M; reproxalap NDA on track for Q4 2022; cash $185M
---------------------------------------------------------------------------

- Net loss of $14.6M ($0.25 per share) for Q3 2022 vs $15.8M ($0.27) for Q3 2021.
- Cash, cash equivalents, and marketable securities of $185.3M as of Sep 30, 2022; expected to fund operations through end of 2023.
- NDA submission for reproxalap in dry eye disease remains on schedule for Q4 2022; package includes data from five adequate and well-controlled trials.
- Pre-NDA meeting with FDA scheduled in Q4 2022 to discuss ADX-2191 for primary vitreoretinal lymphoma; NDA possible by end of 2022.
- Top-line results from Phase 2 trial of ADX-629 in acute alcoholic hepatitis expected by end of 2022; ADX-2191 retinitis pigmentosa trial results expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/0001157523-22-001587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/a52965769.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer